Targeting the mammalian target of rapamycin (mTOR) in cancer therapy: Lessons from past and future perspectives

Cancers

Volumn 3, Issue 2, 2011, Pages 2478-2500

  Dufour, Marc ^a   Dormond Meuwly, Anne ^a   Demartines, Nicolas ^a   Dormond, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cancer; mTOR; Rapalogs; Signaling; Therapy

Indexed keywords

ADENYLATE KINASE; AZD 8055; BCR ABL PROTEIN; CYCLIN D1; DNA METHYLTRANSFERASE INHIBITOR; ETOPOSIDE; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OSI 027; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; STRESS ACTIVATED PROTEIN KINASE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WYE 132;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; COLON CARCINOMA; COMPETITIVE INHIBITION; DRUG BINDING SITE; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; INTRACELLULAR SIGNALING; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; MANTLE CELL LYMPHOMA; MEMORY T LYMPHOCYTE; MULTIPLE MYELOMA; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; REVIEW; RIBOSOME; SKIN CANCER; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 79959693748     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3022478     Document Type: Review

References (134)

1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
2. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28, 1075-1083.
3. Zoncu, R.; Efeyan, A.; Sabatini, D.M. MTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12, 21-35.
4. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C.J.; Zuelke, C.; Farkas, S.; Anthuber, M.; et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat. Med. 2002, 8, 128-135.
5. Saunders, R.N.; Metcalfe, M.S.; Nicholson, M.L. Rapamycin in transplantation: A review of the evidence. Kidney Int. 2001, 59, 3-16.
6. Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell 2006, 124, 471-484.
7. Easton, J.B.; Houghton, P.J. MTOR and cancer therapy. Oncogene 2006, 25, 6436-6446.
8. Alessi, D.R.; Pearce, L.R.; Garcia-Martinez, J.M. New insights into mTOR signaling: mTORC2 and beyond. Sci. Signal. 2009, 2, p e27.
9. Sancak, Y.; Thoreen, C.C.; Peterson, T.R.; Lindquist, R.A.; Kang, S.A.; Spooner, E.; Carr, S.A.; Sabatini, D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 2007, 25, 903-915.
10. Ma, L.; Chen, Z.; Erdjument-Bromage, H.; Tempst, P.; Pandolfi, P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121, 179-193.
11. Carriere, A.; Cargnello, M.; Julien, L.A.; Gao, H.; Bonneil, E.; Thibault, P.; Roux, P.P. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr. Biol. 2008, 18, 1269-1277.
12. Inoki, K.; Zhu, T.; Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115, 577-590.
13. Corradetti, M.N.; Inoki, K.; Bardeesy, N.; DePinho, R.A.; Guan, K.L. Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Gene. Dev. 2004, 18, 1533-1538.
14. DeYoung, M.P.; Horak, P.; Sofer, A.; Sgroi, D.; Ellisen, L.W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Gene. Dev. 2008, 22, 239-251.
15. Sancak, Y.; Peterson, T.R.; Shaul, Y.D.; Lindquist, R.A.; Thoreen, C.C.; Bar-Peled, L.; Sabatini, D.M. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320, 1496-1501.
16. Sancak, Y.; Bar-Peled, L.; Zoncu, R.; Markhard, A.L.; Nada, S.; Sabatini, D.M. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141, 290-303.
17. Feng, Z.; Hu, W.; de Stanchina, E.; Teresky, A.K.; Jin, S.; Lowe, S.; Levine, A.J. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007, 67, 3043-3053.
18. Zinzalla, V.; Stracka, D.; Oppliger, W.; Hall, M.N. Activation of mTORC2 by association with the ribosome. Cell 2011, 144, 757-768.
19. Gan, X.; Wang, J.; Su, B.; Wu, D. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 2011, 286, 10998-11002.
20. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S.M.; Riggins, G.J.; et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304, 554.
21. Philp, A.J.; Campbell, I.G.; Leet, C.; Vincan, E.; Rockman, S.P.; Whitehead, R.H.; Thomas, R.J.; Phillips, W.A. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61, 7426-7429.
22. Carpten, J.D.; Faber, A.L.; Horn, C.; Donoho, G.P.; Briggs, S.L.; Robbins, C.M.; Hostetter, G.; Boguslawski, S.; Moses, T.Y.; Savage, S.; et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448, 439-444.
23. Shoji, K.; Oda, K.; Nakagawa, S.; Hosokawa, S.; Nagae, G.; Uehara, Y.; Sone, K.; Miyamoto, Y.; Hiraike, H.; Hiraike-Wada, O.; et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br. J. Cancer 2009, 101, 145-148.
24. Lim, K.H.; Counter, C.M. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 2005, 8, 381-392.
25. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S.I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275, 1943-1947.
26. Guertin, D.A.; Stevens, D.M.; Saitoh, M.; Kinkel, S.; Crosby, K.; Sheen, J.H.; Mullholland, D.J.; Magnuson, M.A.; Wu, H.; Sabatini, D.M. MTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009, 15, 148-159.
27. Thoreen, C.C.; Sabatini, D.M. Rapamycin inhibits mTORC1, but not completely. Autophagy 2009, 5, 725-726.
28. Sarbassov, D.D.; Ali, S.M.; Sengupta, S.; Sheen, J.H.; Hsu, P.P.; Bagley, A.F.; Markhard, A.L.; Sabatini, D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22, 159-168.
29. Ma, X.M.; Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10, 307-318.
30. Dilling, M.B.; Germain, G.S.; Dudkin, L.; Jayaraman, A.L.; Zhang, X.; Harwood, F.C.; Houghton, P.J. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J. Biol. Chem. 2002, 277, 13907-13917.
31. Kawamata, S.; Sakaida, H.; Hori, T.; Maeda, M.; Uchiyama, T. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998, 91, 561-569.
32. Nagamine, T.; Makela, J.; Mima, T.; Mikuni, N.; Nishitani, N.; Satoh, T.; Ikeda, A.; Shibasaki, H. Serial processing of the somesthetic information revealed by different effects of stimulus rate on the somatosensory-evoked potentials and magnetic fields. Brain Res. 1998, 791, 200-208.
33. Fasolo, A.; Sessa, C. MTOR inhibitors in the treatment of cancer. Exp. Opin. Investig. Drugs 2008, 17, 1717-1734.
34. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 2271-2281.
35. Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grunwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372, 449-456.
36. Hess, G.; Herbrecht, R.; Romaguera, J.; Verhoef, G.; Crump, M.; Gisselbrecht, C.; Laurell, A.; Offner, F.; Strahs, A.; Berkenblit, A.; et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2009, 27, 3822-3829.
37. Yao, J.C.; Shah, M.H.; Ito, T.; Bohas, C.L.; Wolin, E.M.; Van Cutsem, E.; Hobday, T.J.; Okusaka, T.; Capdevila, J.; de Vries, E.G.; et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364, 514-523.
38. Roulin, D.; Demartines, N.; Dormond, O. ATP-competitive inhibitors of mTOR: New perspectives in the treatment of renal cell carcinoma. Biochem. Soc. Trans. 2011, 39, 492-494.
39. Jares, P.; Colomer, D.; Campo, E. Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat. Rev. Cancer 2007, 7, 750-762.
40. Missiaglia, E.; Dalai, I.; Barbi, S.; Beghelli, S.; Falconi, M.; della Peruta, M.; Piemonti, L.; Capurso, G.; Di Florio, A.; delle Fave, G.; et al. Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 2010, 28, 245-255.
41. Fasolo, A.; Sessa, C. Current and future directions in mammalian target of rapamycin inhibitors development. Exp. Opin. Investig. Drugs 2011, 20, 381-394.
42. McMenamin, M.E.; Soung, P.; Perera, S.; Kaplan, I.; Loda, M.; Sellers, W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999, 59, 4291-4296.
43. Kremer, C.L.; Klein, R.R.; Mendelson, J.; Browne, W.; Samadzedeh, L.K.; Vanpatten, K.; Highstrom, L.; Pestano, G.A.; Nagle, R.B. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006, 66, 1203-1212.
44. Morgan, T.M.; Koreckij, T.D.; Corey, E. Targeted therapy for advanced prostate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr. Cancer Drug Targets 2009, 9, 237-249.
45. Armstrong, A.J.; Netto, G.J.; Rudek, M.A.; Halabi, S.; Wood, D.P.; Creel, P.A.; Mundy, K.; Davis, S.L.; Wang, T.; Albadine, R.; et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin. Cancer Res. 2010, 16, 3057-3066.
46. Amato, R.J.; Jac, J.; Mohammad, T.; Saxena, S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin. Genitourin. Cancer 2008, 6, 97-102.
47. Kelly, K.R.; Rowe, J.H.; Padmanabhan, S.; Nawrocki, S.T.; Carew, J.S. Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol. 2011, 6, 53-61.
48. Chapuis, N.; Tamburini, J.; Green, A.S.; Willems, L.; Bardet, V.; Park, S.; Lacombe, C.; Mayeux, P.; Bouscary, D. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010, 24, 1686-1699.
49. Recher, C.; Beyne-Rauzy, O.; Demur, C.; Chicanne, G.; Dos Santos, C.; Mas, V.M.; Benzaquen, D.; Laurent, G.; Huguet, F.; Payrastre, B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105, 2527-2534.
50. Perl, A.E.; Kasner, M.T.; Tsai, D.E.; Vogl, D.T.; Loren, A.W.; Schuster, S.J.; Porter, D.L.; Stadtmauer, E.A.; Goldstein, S.C.; Frey, N.V.; et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin. Cancer Res. 2009, 15, 6732-6739.
51. Sillaber, C.; Mayerhofer, M.; Bohm, A.; Vales, A.; Gruze, A.; Aichberger, K.J.; Esterbauer, H.; Pfeilstocker, M.; Sperr, W.R.; Pickl, W.F.; et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur. J. Clin. Invest. 2008, 38, 43-52.
52. Younes, H.; Leleu, X.; Hatjiharissi, E.; Moreau, A.S.; Hideshima, T.; Richardson, P.; Anderson, K.C.; Ghobrial, I.M. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin. Cancer Res. 2007, 13, 3771-3775.
53. Farag, S.S.; Zhang, S.; Jansak, B.S.; Wang, X.; Kraut, E.; Chan, K.; Dancey, J.E.; Grever, M.R. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk. Res. 2009, 33, 1475-1480.
54. Zent, C.S.; LaPlant, B.R.; Johnston, P.B.; Call, T.G.; Habermann, T.M.; Micallef, I.N.; Witzig, T.E. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010, 116, 2201-2207.
55. Decker, T.; Sandherr, M.; Goetze, K.; Oelsner, M.; Ringshausen, I.; Peschel, C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann. Hematol. 2009, 88, 221-227.
56. Ben Sahra, I.; Le Marchand-Brustel, Y.; Tanti, J.F.; Bost, F. Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol. Cancer Ther. 2010, 9, 1092-1099.
57. Evans, J.M.; Donnelly, L.A.; Emslie-Smith, A.M.; Alessi, D.R.; Morris, A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330, 1304-1305.
58. Bowker, S.L.; Majumdar, S.R.; Veugelers, P.; Johnson, J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29, 254-258.
59. Dowling, R.J.; Goodwin, P.J.; Stambolic, V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011, 9, 33.
60. Ben Sahra, I.; Regazzetti, C.; Robert, G.; Laurent, K.; Le Marchand Brustel, Y.; Auberger, P.; Tanti, J.F.; Giorgetti Peraldi, S.; Bost, F. Metformin, independent of AMPK, induces mTOR inhibition and cell cycle arrest through REDD1. Cancer Res. 2011, doi: 10.1158/0008-5472.CAN-10-1769.
61. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108, 1167-1174.
62. Neshat, M.S.; Mellinghoff, I.K.; Tran, C.; Stiles, B.; Thomas, G.; Petersen, R.; Frost, P.; Gibbons, J.J.; Wu, H.; Sawyers, C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 2001, 98, 10314-10319.
63. Sawyers, C.L. The cancer biomarker problem. Nature 2008, 452, 548-552.
64. Swanton, C.; Larkin, J.M.; Gerlinger, M.; Eklund, A.C.; Howell, M.; Stamp, G.; Downward, J.; Gore, M.; Futreal, P.A.; Escudier, B.; et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med. 2010, 2, 53.
65. Boulay, A.; Zumstein-Mecker, S.; Stephan, C.; Beuvink, I.; Zilbermann, F.; Haller, R.; Tobler, S.; Heusser, C.; O'Reilly, T.; Stolz, B.; et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004, 64, 252-261.
66. Penn, I. Cancers complicating organ transplantation. N. Engl. J. Med. 1990, 323, 1767-1769.
67. Hojo, M.; Morimoto, T.; Maluccio, M.; Asano, T.; Morimoto, K.; Lagman, M.; Shimbo, T.; Suthanthiran, M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397, 530-534.
68. Basu, A.; Contreras, A.G.; Datta, D.; Flynn, E.; Zeng, L.; Cohen, H.T.; Briscoe, D.M.; Pal, S. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res. 2008, 68, 5689-5698.
69. Geissler, E.K.; Schlitt, H.J.; Thomas, G. MTOR, cancer and transplantation. Am. J. Transplant. 2008, 8, 2212-2218.
70. Salgo, R.; Gossmann, J.; Schofer, H.; Kachel, H.G.; Kuck, J.; Geiger, H.; Kaufmann, R.; Scheuermann, E.H. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: Reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am. J. Transplant. 2010, 10, 1385-1393.
71. Schena, F.P.; Pascoe, M.D.; Alberu, J.; del Carmen Rial, M.; Oberbauer, R.; Brennan, D.C.; Campistol, J.M.; Racusen, L.; Polinsky, M.S.; Goldberg-Alberts, R.; et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-Month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87, 233-242.
72. Monaco, A.P. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009, 87, 157-163.
73. Campistol, J.M.; Gutierrez-Dalmau, A.; Torregrosa, J.V. Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004, 77, 760-762.
74. Stallone, G.; Schena, A.; Infante, B.; Di Paolo, S.; Loverre, A.; Maggio, G.; Ranieri, E.; Gesualdo, L.; Schena, F.P.; Grandaliano, G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 2005, 352, 1317-1323.
75. Dormond, O.; Madsen, J.C.; Briscoe, D.M. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J. Biol. Chem. 2007, 282, 23679-23686.
76. Barozzi, P.; Bonini, C.; Potenza, L.; Masetti, M.; Cappelli, G.; Gruarin, P.; Whitby, D.; Gerunda, G.E.; Mondino, A.; Riva, G.; et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008, 86, 738-744.
77. Ozaki, K.S.; Camara, N.O.; Galante, N.Z.; Camargo, L.F.; Pacheco-Silva, A. Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients. Int. Immunopharmacol. 2005, 5, 103-106.
78. Araki, K.; Turner, A.P.; Shaffer, V.O.; Gangappa, S.; Keller, S.A.; Bachmann, M.F.; Larsen, C.P.; Ahmed, R. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460, 108-112.
79. Pearce, E.L.; Walsh, M.C.; Cejas, P.J.; Harms, G.M.; Shen, H.; Wang, L.S.; Jones, R.G.; Choi, Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460, 103-107.
80. Rao, R.R.; Li, Q.; Odunsi, K.; Shrikant, P.A. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010, 32, 67-78.
81. Ferrer, I.R.; Araki, K.; Ford, M.L. Paradoxical aspects of rapamycin immunobiology in transplantation. Am. J. Transplant. 2011, 11, 654-659.
82. Thomson, A.W.; Turnquist, H.R.; Raimondi, G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 2009, 9, 324-337.
83. Hackstein, H.; Taner, T.; Zahorchak, A.F.; Morelli, A.E.; Logar, A.J.; Gessner, A.; Thomson, A.W. Rapamycin inhibits IL-4-Induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101, 4457-4463.
84. Weiner, S.M.; Sellin, L.; Vonend, O.; Schenker, P.; Buchner, N.J.; Flecken, M.; Viebahn, R.; Rump, L.C. Pneumonitis associated with sirolimus: Clinical characteristics, risk factors and outcome-A single-centre experience and review of the literature. Nephrol. Dial. Transplant. 2007, 22, 3631-3637.
85. Saemann, M.D.; Haidinger, M.; Hecking, M.; Horl, W.H.; Weichhart, T. The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am. J. Transplant. 2009, 9, 2655-2661.
86. Minhajuddin, M.; Fazal, F.; Bijli, K.M.; Amin, M.R.; Rahman, A. Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells. J. Immunol. 2005, 174, 5823-5829.
87. Efeyan, A.; Sabatini, D.M. MTOR and cancer: Many loops in one pathway. Curr. Opin. Cell Biol. 2010, 22, 169-176.
88. Zhang, H.; Cicchetti, G.; Onda, H.; Koon, H.B.; Asrican, K.; Bajraszewski, N.; Vazquez, F.; Carpenter, C.L.; Kwiatkowski, D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 2003, 112, 1223-1233.
89. Harrington, L.S.; Findlay, G.M.; Gray, A.; Tolkacheva, T.; Wigfield, S.; Rebholz, H.; Barnett, J.; Leslie, N.R.; Cheng, S.; Shepherd, P.R.; et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell. Biol. 2004, 166, 213-223.
90. O'Reilly, K.E.; Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66, 1500-1508.
91. Tabernero, J.; Rojo, F.; Calvo, E.; Burris, H.; Judson, I.; Hazell, K.; Martinelli, E.; Ramony Cajal, S.; Jones, S.; Vidal, L.; et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26, 1603-1610.
92. Cloughesy, T.F.; Yoshimoto, K.; Nghiemphu, P.; Brown, K.; Dang, J.; Zhu, S.; Hsueh, T.; Chen, Y.; Wang, W.; Youngkin, D.; et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5, e8.
93. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A.T.; Thomas, G.; Kozma, S.C.; et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118, 3065-3074.
94. Wang, X.; Hawk, N.; Yue, P.; Kauh, J.; Ramalingam, S.S.; Fu, H.; Khuri, F.R.; Sun, S.Y. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol. Ther. 2008, 7, 1952-1958.
95. Kinkade, C.W.; Castillo-Martin, M.; Puzio-Kuter, A.; Yan, J.; Foster, T.H.; Gao, H.; Sun, Y.; Ouyang, X.; Gerald, W.L.; Cordon-Cardo, C.; Abate-Shen, C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 2008, 118, 3051-3064.
96. Dormond-Meuwly, A.; Roulin, D.; Dufour, M.; Benoit, M.; Demartines, N.; Dormond, O. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors. Biochem. Biophys. Res. Commun. 2011, 407, 714-719.
97. Wang, X.; Yue, P.; Chan, C.B.; Ye, K.; Ueda, T.; Watanabe-Fukunaga, R.; Fukunaga, R.; Fu, H.; Khuri, F.R.; Sun, S.Y. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol. Cell. Biol. 2007, 27, 7405-7413.
98. Mamane, Y.; Petroulakis, E.; Martineau, Y.; Sato, T.A.; Larsson, O.; Rajasekhar, V.K.; Sonenberg, N. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One 2007, 2, e242.
99. Benoit, M.; Dormond-Meuwly, A.; Demartines, N.; Dormond, O. Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of rapamycin in LS174T colon cancer cells. J. Surg. Res. 2011, 167, e193-e198.
100. Baumann, P.; Hagemeier, H.; Mandl-Weber, S.; Franke, D.; Schmidmaier, R. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anticancer Drugs 2009, 20, 259-266.
101. Vilar, E.; Perez-Garcia, J.; Tabernero, J. Pushing the envelope in the mTOR pathway: The second generation of inhibitors. Mol. Cancer Ther. 2011, 10, 395-403.
102. Rao, R.D.; Mladek, A.C.; Lamont, J.D.; Goble, J.M.; Erlichman, C.; James, C.D.; Sarkaria, J.N. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005, 7, 921-929.
103. Birle, D.C.; Hedley, D.W. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol. Cancer Ther. 2006, 5, 2494-2502.
104. Ikezoe, T.; Nishioka, C.; Bandobashi, K.; Yang, Y.; Kuwayama, Y.; Adachi, Y.; Takeuchi, T.; Koeffler, H.P.; Taguchi, H. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk. Res. 2007, 31, 673-682.
105. Chappell, W.H.; Steelman, L.S.; Long, J.M.; Kempf, R.C.; Abrams, S.L.; Franklin, R.A.; Basecke, J.; Stivala, F.; Donia, M.; Fagone, P.; et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2, 135-164.
106. Cirstea, D.; Hideshima, T.; Rodig, S.; Santo, L.; Pozzi, S.; Vallet, S.; Ikeda, H.; Perrone, G.; Gorgun, G.; Patel, K.; et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol. Cancer Ther. 2010, 9, 963-975.
107. Abdelnour-Berchtold, E.; Cerantola, Y.; Roulin, D.; Dormond-Meuwly, A.; Demartines, N.; Dormond, O. Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin. Anticancer Res. 2010, 30, 799-804.
108. Carracedo, A.; Baselga, J.; Pandolfi, P.P. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008, 7, 3805-3809.
109. Wang, Z.; Zhou, J.; Fan, J.; Qiu, S.J.; Yu, Y.; Huang, X.W.; Tang, Z.Y. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res. 2008, 14, 5124-5130.
110. Lee, N.; Woodrum, C.L.; Nobil, A.M.; Rauktys, A.E.; Messina, M.P.; Dabora, S.L. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 2009, 9, 8.
111. Mahalingam, D.; Medina, E.C.; Esquivel, J.A., 2nd; Espitia, C.M.; Smith, S.; Oberheu, K.; Swords, R.; Kelly, K.R.; Mita, M.M.; et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 2010, 16, 141-153.
112. Zhang, Y.J.; Zhao, S.L.; Tian, X.Q.; Sun, D.F.; Xiong, H.; Dai, Q.; Li, X.Q.; Fang, J.Y. Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer. Int. J. Colorectal Dis. 2009, 24, 629-639.
113. Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M.A.; Hall, A.; Hall, M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 2004, 6, 1122-1128.
114. Garcia-Echeverria, C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg. Med. Chem. Lett. 2010, 20, 4308-4312.
115. Roulin, D.; Cerantola, Y.; Dormond-Meuwly, A.; Demartines, N.; Dormond, O. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol. Cancer 2010, 9, 57.
116. Albert, S.; Serova, M.; Dreyer, C.; Sablin, M.P.; Faivre, S.; Raymond, E. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Exp. Opin. Investig. Drugs 2010, 19, 919-930.
117. Chresta, C.M.; Davies, B.R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S.E.; Vincent, J.P.; Ellston, R.; Jones, D.; Sini, P.; et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010, 70, 288-298.
118. Marshall, G.; Howard, Z.; Dry, J.; Fenton, S.; Heathcote, D.; Gray, N.; Keen, H.; Logie, A.; Holt, S.; Smith, P.; et al. Benefits of mTOR kinase targeting in oncology: Pre-clinical evidence with AZD8055. Biochem. Soc. Trans. 2011, 39, 456-459.
119. Yu, K.; Shi, C.; Toral-Barza, L.; Lucas, J.; Shor, B.; Kim, J.E.; Zhang, W.G.; Mahoney, R.; Gaydos, C.; Tardio, L.; et al. Beyond rapalog therapy: Preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010, 70, 621-631.
120. Falcon, B.L.; Barr, S.; Gokhale, P.C.; Chou, J.; Fogarty, J.; Depeille, P.; Miglarese, M.; Epstein, D.M.; McDonald, D.M. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011, 71, 1573-1583.
121. Janes, M.R.; Limon, J.J.; So, L.; Chen, J.; Lim, R.J.; Chavez, M.A.; Vu, C.; Lilly, M.B.; Mallya, S.; Ong, S.T.; et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 2010, 16, 205-213.
122. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P.J.; Valero, V.; Guzman, M.; Botero, M.L.; Llonch, E.; Atzori, F.; di Cosimo, S.; et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68, 8022-8030.
123. Brachmann, S.M.; Hofmann, I.; Schnell, C.; Fritsch, C.; Wee, S.; Lane, H.; Wang, S.; Garcia-Echeverria, C.; Maira, S.M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA 2009, 106, 22299-22304.
124. Cho, D.C.; Cohen, M.B.; Panka, D.J.; Collins, M.; Ghebremichael, M.; Atkins, M.B.; Signoretti, S.; Mier, J.W. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 2010, 16, 3628-3638.
125. Chapuis, N.; Tamburini, J.; Green, A.S.; Vignon, C.; Bardet, V.; Neyret, A.; Pannetier, M.; Willems, L.; Park, S.; Macone, A.; et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res. 2010, 16, 5424-5435.
126. Roccaro, A.M.; Sacco, A.; Husu, E.N.; Pitsillides, C.; Vesole, S.; Azab, A.K.; Azab, F.; Melhem, M.; Ngo, H.T.; Quang, P.; et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010, 115, 559-569.
127. Chiarini, F.; Grimaldi, C.; Ricci, F.; Tazzari, P.L.; Evangelisti, C.; Ognibene, A.; Battistelli, M.; Falcieri, E.; Melchionda, F.; Pession, A.; et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res. 2010, 70, 8097-8107.
128. Engelman, J.A.; Chen, L.; Tan, X.; Crosby, K.; Guimaraes, A.R.; Upadhyay, R.; Maira, M.; McNamara, K.; Perera, S.A.; Song, Y.; et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14, 1351-1356.
129. Santiskulvong, C.; Konecny, G.E.; Fekete, M.; Chen, K.Y.; Karam, A.; Mulholland, D.; Eng, C.; Wu, H.; Song, M.; Dorigo, O. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin. Cancer Res. 2011, 17, 2373-2384.
130. Garcia-Martinez, J.M.; Wullschleger, S.; Preston, G.; Guichard, S.; Fleming, S.; Alessi, D.R.; Duce, S.L. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br. J. Cancer 2011, 104, 1116-1125.
131. Thoreen, C.C.; Kang, S.A.; Chang, J.W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L.J.; Sim, T.; Sabatini, D.M.; Gray, N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284, 8023-8032.
132. Feldman, M.E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z.A.; Ruggero, D.; Shokat, K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7, e38.
133. Garcia-Martinez, J.M.; Moran, J.; Clarke, R.G.; Gray, A.; Cosulich, S.C.; Chresta, C.M.; Alessi, D.R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 2009, 421, 29-42.
134. Guertin, D.A.; Stevens, D.M.; Thoreen, C.C.; Burds, A.A.; Kalaany, N.Y.; Moffat, J.; Brown, M.; Fitzgerald, K.J.; Sabatini, D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 2006, 11, 859-871.